---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-008512"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T16:01:39.066050+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics elects Dr. Akintunde Bello to Board of Directors

## Summary
- Board increased to ten directors; Dr. Bello elected as Class II director effective June 10, 2025.
- Term expires at 2026 annual meeting; appointed to Nominating and Corporate Governance Committee.
- Compensation follows standard non-employee director terms as described in the 2025 proxy statement.
- Dr. Bello will enter into the company's standard indemnification agreement.

## SEC filing metadata
- accession: 0001558370-25-008512
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837025008512/0001558370-25-008512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837025008512/xlo-20250610x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-008512
- JSON: https://secwatch.observer/filing/0001558370-25-008512.json
- Plain text: https://secwatch.observer/filing/0001558370-25-008512.txt

## Key facts
- Executive change
  Akintunde Bello was elected as Class II director at Xilio Therapeutics, Inc..
  - Action: elected
  - Role: Class II director
  source text: elected Akintunde Bello, Ph.D., as a Class II director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837025008512/0001558370-25-008512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.